Table 1.
Ten-year relative survival in Japanese cancer patients followed-up between 2002 and 2006 (period approach) and conditional 5-year survival of 5-year survivors (15–99 years old)
| Male |
Female |
|||||
|---|---|---|---|---|---|---|
| Site (ICD-10 code) | n | Ten-year relative survival, % (95% CI) | Conditional 5-year survival of 5-year survivors, % (95% CI) | n | Ten-year relative survival, % (95% CI) | Conditional 5-year survival of 5-year survivors, % (95% CI) |
| Lip, oral cavity, and pharynx (C00–C14) | 4214 | 41.4 (39.4–43.5) | 83.3 (80.4–85.9) | 1857 | 53.6 (50.5–56.5) | 89.3 (85.8–92.0) |
| Esophagus (C15) | 8265 | 24.0 (22.7–25.4) | 74.7 (71.5–77.6) | 1540 | 32.4 (29.2–35.5) | 86.2 (79.8–90.6) |
| Stomach (C16) | 42 930 | 61.3 (60.7–62.0) | 96.8 (96.2–97.3) | 20 778 | 58.2 (57.3–59.0) | 96.5 (95.8–97.1) |
| Colon (C18) | 18 514 | 68.9 (67.9–70.0) | 97.2 (96.3–98.0) | 16 907 | 62.8 (61.8–63.8) | 96.1 (95.3–96.8) |
| Rectum (C19–C20) | 11 922 | 60.8 (59.5–62.0) | 92.7 (91.5–93.8) | 6866 | 63.2 (61.7–64.7) | 94.4 (93.1–95.5) |
| Liver (C22) | 14 230 | 9.6 (9.0–10.3) | 38.0 (35.8–40.2) | 6945 | 9.1 (8.2–10.0) | 38.4 (35.1–41.7) |
| Gallbladder etc. (C23–C24) | 4436 | 18.5 (16.9–20.1) | 85.9 (80.6–89.8) | 5064 | 15.5 (14.3–16.8) | 87.6 (83.2–90.9) |
| Pancreas (C25) | 6310 | 4.6 (3.9–5.4) | 78.8 (70.2–85.2) | 5318 | 4.8 (4.1–5.6) | 81.6 (72.4–88.0) |
| Larynx (C32)† | 2297 | 73.8 (70.8–76.6) | 93.2 (90.3–95.3) | – | – | – |
| Lung (C33–C34) | 30 537 | 18.1 (17.4–18.7) | 79.4 (77.4–81.3) | 12 525 | 31.2 (30.1–32.3) | 84.2 (82.1–86.2) |
| Skin (C43–C44) | 2213 | 86.6 (83.0–89.4) | 96.5 (92.6–98.4) | 2431 | 90.4 (87.5–92.6) | 97.6 (94.7–98.9) |
| Breast (C50) | – | – | – | 28 301 | 79.3 (78.6–79.9) | 90.5 (90.0–91.1) |
| Cervix uteri (C53) | – | – | – | 5106 | 66.1 (64.5–67.7) | 95.4 (94.2–96.4) |
| Corpus uteri (C54) | – | – | – | 4097 | 75.6 (73.7–77.3) | 96.2 (94.6–97.3) |
| Ovary (C56) | – | – | – | 4163 | 43.9 (42.0–45.7) | 85.6 (83.3–87.6) |
| Prostate (C61) | 19 519 | 78.0 (75.8–79.9) | 89.2 (86.9–91.1) | – | – | – |
| Kidney, renal pelvis, ureter etc. (C64–C66, C68) | 4725 | 59.3 (57.1–61.4) | 90.5 (88.1–92.5) | 2374 | 57.1 (54.2–59.8) | 91.5 (88.4–93.9) |
| Bladder (C67) | 5937 | 74.6 (72.6–76.5) | 94.3 (92.4–95.8) | 1928 | 62.8 (59.5–65.8) | 95.3 (91.8–97.3) |
| Brain and CNS (C70–C72, C75.1–C75.3)‡ | 921 | 21.5 (18.6–24.6) | 75.0 (68.1–80.6) | 785 | 24.4 (21.1–27.8) | 84.1 (77.1–89.0) |
| Thyroid (C73) | 1077 | 87.1 (83.2–90.2) | 97.9 (92.9–99.4) | 3713 | 94.8 (93.5–95.9) | 99.3 (98.1–99.7) |
| Malingant lymphoma (C81–C85, C96) | 4577 | 43.1 (41.0–45.1) | 86.9 (84.0–89.4) | 3925 | 50.6 (48.4–52.7) | 87.1 (84.4–89.4) |
| Multiple myeloma (C88–C90) | 1153 | 11.4 (8.9–14.3) | 41.2 (32.7–49.5) | 1090 | 14.3 (11.6–17.2) | 48.4 (40.2–56.1) |
| Leukemia (C91–C95) | 2599 | 20.5 (18.6–22.5) | 80.4 (75.2–84.7) | 1894 | 20.5 (18.4–22.7) | 77.4 (71.9–81.9) |
†
Both sexes combined. ‡;Malignant cases only. –, Not applicable; CI, confidence interval; CNS, central nervous system.